SCHEMBL2292255

SCHEMBL2292255

Cc1cccc(C)c1Nc1c(-c2ccc(O)cc2OCC(N)=O)nc2ccc(F)cn12

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 14/20 0.49
MAPT P10636 13/20 0.49
TP53 P04637 6/20 0.49
POLB P06746 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.42
TRPA1 O75762 1/20 0.42
THRB P10828 2/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 1/20 0.35
GLA P06280 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289236 0.95 TRPA1 (0.45) GAAMAPTTP53POLBSMN1; SMN2
SCHEMBL2290086 0.93 GAA (0.43) GAAMAPTTP53POLBSMN1; SMN2
SCHEMBL2293500 0.92 GAA (0.47) GAAMAPTTP53POLBSMN1; SMN2
SCHEMBL2289462 0.92 GAA (0.47) GAAMAPTTP53POLBSMN1; SMN2
SCHEMBL2287174 0.91 GAA (0.44) GAAMAPTTP53POLBSMN1; SMN2
SCHEMBL2290123 0.91 GAA (0.43) GAAMAPTTP53POLBSMN1; SMN2
SCHEMBL2287600 0.90 TRPA1 (0.45) GAAMAPTTP53POLBSMN1; SMN2
SCHEMBL2287300 0.89 TRPA1 (0.43) GAAMAPTTP53POLBSMN1; SMN2
SCHEMBL2295304 0.89 TRPA1 (0.41) GAAMAPTTP53POLBSMN1; SMN2
SCHEMBL2291158 0.89 TRPA1 (0.43) GAAMAPTTP53POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 GAA 1202/4885MAPT 1138/4885TP53 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.